Executive Insights | Oct 15, 12:30 PM ET | Disrupting the Rx Supply Chain, How Will Going DiRx Work?

Overview

Satish Srinivasan, Founder & Chief Executive Officer at DiRx, will join us in the studio for a discussion about the opportunity to disrupt the pharmaceutical supply chain by going direct to both drug manufacturers and consumers.  We've been following GoodRx (GDRX) closely and its focus on manufacturer marketing, relationships with PBMs, etc., as well as monitoring what's happening at the pharmacy level through our field work.  Benefits consultants and employers (i.e., benefits directors) are not shy about their frustration with PBMs and drug pricing, and the Big Three PBMs (UNH/Optum, CVS, and CI/Express) and generic "power buyers" (Red Oak Sourcing, ClarusONE, and WBAD) just keep doing what they do: print money.  DiRx, which is focused on generic supply and cash pay, for now, just launched at the end of August, so we'll get a real-time view of how things are progressing, end markets' receptivity to the model, how the company differs from others (Amazon Pharmacy, HIMS, Ro, et al.), and much more. 

Hedgeye Health Care Sector Head Tom Tobin will lead the discussion, which we expect to cover:

1. Why consumers are still struggling with drug costs despite high generic penetration
2. The addressable market for drug coupons and a new offering like DiRx's - what's max mail penetration?
3. Customer acquisition costs - how CAC is trending for digital/direct-to-consumer health companies and why
4. Where Amazon is heading
5. The nuances of direct purchasing
6. Generic pricing and quantifying the Rx savings opportunity

Please send any questions for Satish and Tom to .

About the Speaker

Satish Srinivasan is the Founder & CEO of DiRx (Direct + Rx, pronounced Directs; July 2020 - present), a new digital health platform designed to improve medication affordability for Americans who are unable to access it under the health insurance framework.  He has over 25 years of experience in building and managing generic pharmaceutical companies, which gives him a deep understanding of channel economics and global supply chains as they relate to the broader healthcare system.  In addition to a strategic mindset, his ‘people first’ approach has been the hallmark of his professional track record and successes.  Satish's recent prior experience includes President - North America for Sentiss Pharma (May 2018 - March 2020), which specializes in the development, manufacture, and commercialization of sterile generic and specialty pharmaceutical products focused on the ophthalmic and inhalation segments; as well as leadership positions at other generic manufacturers including Rising Pharmaceuticals, where he was President & COO (July 2013 - December 2016); and OrchidPharma, where he was President & CEO (July 2010 - June 2013).  Satish holds a Master’s in Science, Pharmacy Administration.

We hope you can join us! 

Thomas Tobin
Managing Director


Twitter
LinkedIn

Justin Venneri
Director, Primary Research


Twitter
LinkedIn

William McMahon
Analyst


Twitter
LinkedIn